{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T03:57:39Z","timestamp":1789444659775,"version":"build-2803163510"},"reference-count":25,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T00:00:00Z","timestamp":1662681600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>The humoral response to SARS-CoV-2 can provide immunity and prevent reinfection. However, less is known about how the diversity, magnitude, and length of the antibody response after a primary infection is associated with symptoms, post-infection immunity, and post-vaccinated immunity.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>Cook County Health employees provided blood samples and completed an online survey 8\u201310 weeks after a PCR-confirmed positive SARS-CoV-2 test (pre-vaccinated, N = 41) and again, 1\u20134 weeks after completion of a 2-dose series mRNA BNT162b2 COVID-19 vaccine (post-vaccinated, N = 27). Associations were evaluated between SARS-CoV-2 antibody titers, participant demographics, and clinical characteristics. Antibody titers and angiotensin-converting enzyme 2 (ACE2) neutralization were compared before and after the mRNA BNT162b2 COVID-19 vaccine.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Antibody titers to the spike protein (ST4), receptor binding domain (RBD), and RBD mutant D614G were significantly associated with anosmia and ageusia, cough, and fever. Spike protein antibody titers and ACE2 neutralization were significantly higher in participants that presented with these symptoms. Antibody titers to the spike protein N-terminal domain (NTD), RBD, and ST4, and ACE2 IC50 were significantly higher in all post-vaccinated participant samples compared to pre-vaccinated participant sample, and not dependent on previously reported symptoms.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Spike protein antibody titers and ACE2 neutralization are associated with the presentation of anosmia and ageusia, cough, and fever after SARS-CoV-2 infection. Symptom response to previous SARS-CoV-2 infection did not influence the antibody response from subsequent vaccination. These results suggest a relationship between infection severity and the magnitude of the immune response and provide meaningful insights into COVID-19 immunity according to discrete symptom presentation.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0273323","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T19:51:38Z","timestamp":1662753098000},"page":"e0273323","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["COVID-19 symptom relationship to antibody response and ACE2 neutralization in recovered health systems employees before and after mRNA BNT162b2 COVID-19 vaccine"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4699-5467","authenticated-orcid":true,"given":"Gregory","family":"Huhn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh","family":"Poorbaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Beasley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Nirula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Brothers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Welbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheena","family":"Gillani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Morack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kody","family":"Keckler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Benschop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,9,9]]},"reference":[{"key":"pone.0273323.ref001","unstructured":"COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU): Johns Hopkins University and Medicine; 2021. https:\/\/coronavirus.jhu.edu\/map.html."},{"issue":"10","key":"pone.0273323.ref002","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41577-020-00451-5","article-title":"COVID-19 herd immunity: where are we?","volume":"20","author":"A Fontanet","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"pone.0273323.ref003","doi-asserted-by":"crossref","first-page":"610688","DOI":"10.3389\/fimmu.2020.610688","article-title":"Humoral Responses and Serological Assays in SARS-CoV-2 Infections","volume":"11","author":"Y Galipeau","year":"2020","journal-title":"Front Immunol"},{"issue":"3","key":"pone.0273323.ref004","doi-asserted-by":"crossref","first-page":"100040","DOI":"10.1016\/j.xcrm.2020.100040","article-title":"Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients","volume":"1","author":"MS Suthar","year":"2020","journal-title":"Cell Rep Med"},{"issue":"5","key":"pone.0273323.ref005","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.chom.2021.03.005","article-title":"Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite","volume":"29","author":"G Cerutti","year":"2021","journal-title":"Cell Host Microbe"},{"issue":"1","key":"pone.0273323.ref006","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/s41467-020-20501-9","article-title":"Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry","volume":"12","author":"J Ge","year":"2021","journal-title":"Nat Commun"},{"key":"pone.0273323.ref007","doi-asserted-by":"crossref","first-page":"584251","DOI":"10.3389\/fmicb.2020.584251","article-title":"Anti-spike, Anti-nucleocapsid and Neutralizing Antibodies in SARS-CoV-2 Inpatients and Asymptomatic Individuals","volume":"11","author":"E Brochot","year":"2020","journal-title":"Front Microbiol"},{"issue":"1","key":"pone.0273323.ref008","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1038\/s41467-021-23036-9","article-title":"A SARS-CoV-2 antibody curbs viral nucleocapsid protein-induced complement hyperactivation","volume":"12","author":"S Kang","year":"2021","journal-title":"Nat Commun"},{"issue":"6529","key":"pone.0273323.ref009","article-title":"Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection","volume":"371","author":"JM Dan","year":"2021","journal-title":"Science"},{"issue":"3","key":"pone.0273323.ref010","doi-asserted-by":"crossref","DOI":"10.1172\/JCI144930","article-title":"Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates","volume":"131","author":"J Boonyaratanakornkit","year":"2021","journal-title":"J Clin Invest"},{"key":"pone.0273323.ref011","unstructured":"FACT SHEET FOR HEALTHCARE PROVIDERS ADMINISTERING VACCINE (VACCINATION PROVIDERS) FDA2022 [https:\/\/www.fda.gov\/media\/159312\/download."},{"key":"pone.0273323.ref012","article-title":"The effect of anti-SARS-CoV-2 monoclonal antibody, bamlanivimab, on endogenous immune response to COVID-19 vaccination","author":"RJ Benschop","year":"2021","journal-title":"medRxiv"},{"key":"pone.0273323.ref013","doi-asserted-by":"crossref","first-page":"790469","DOI":"10.3389\/fimmu.2021.790469","article-title":"Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together","volume":"12","author":"L Zhang","year":"2021","journal-title":"Front Immunol"},{"issue":"4","key":"pone.0273323.ref014","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1208\/s12248-014-9599-2","article-title":"Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations","volume":"16","author":"G Shankar","year":"2014","journal-title":"AAPS J"},{"issue":"1","key":"pone.0273323.ref015","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1038\/s41467-021-22958-8","article-title":"Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival","volume":"12","author":"S Dispinseri","year":"2021","journal-title":"Nat Commun"},{"issue":"7821","key":"pone.0273323.ref016","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41586-020-2456-9","article-title":"Convergent antibody responses to SARS-CoV-2 in convalescent individuals","volume":"584","author":"DF Robbiani","year":"2020","journal-title":"Nature"},{"key":"pone.0273323.ref017","doi-asserted-by":"crossref","first-page":"628971","DOI":"10.3389\/fimmu.2020.628971","article-title":"Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses","volume":"11","author":"S Schlickeiser","year":"2020","journal-title":"Front Immunol"},{"issue":"12","key":"pone.0273323.ref018","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1038\/s41564-020-00813-8","article-title":"Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans","volume":"5","author":"J Seow","year":"2020","journal-title":"Nat Microbiol"},{"issue":"12","key":"pone.0273323.ref019","doi-asserted-by":"crossref","first-page":"e666","DOI":"10.1016\/S2666-5247(21)00219-6","article-title":"The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study","volume":"2","author":"JP Townsend","year":"2021","journal-title":"Lancet Microbe"},{"issue":"4","key":"pone.0273323.ref020","first-page":"812","article-title":"Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19","volume":"182","author":"B Korber","year":"2020","journal-title":"Virus. Cell"},{"issue":"20","key":"pone.0273323.ref021","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJMc2102051","article-title":"Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine","volume":"384","author":"T Bradley","year":"2021","journal-title":"N Engl J Med"},{"issue":"7867","key":"pone.0273323.ref022","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41586-021-03696-9","article-title":"Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection","volume":"595","author":"Z Wang","year":"2021","journal-title":"Nature"},{"issue":"3","key":"pone.0273323.ref023","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19","volume":"384","author":"DM Weinreich","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"pone.0273323.ref024","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1001\/jama.2021.0202","article-title":"Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial","volume":"325","author":"RL Gottlieb","year":"2021","journal-title":"JAMA"},{"issue":"10","key":"pone.0273323.ref025","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1172\/JCI138759","article-title":"Kinetics of viral load and antibody response in relation to COVID-19 severity","volume":"130","author":"Y Wang","year":"2020","journal-title":"J Clin Invest"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0273323","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T19:52:19Z","timestamp":1662753139000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0273323"}},"subtitle":[],"editor":[{"given":"Jayanta","family":"Bhattacharya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,9,9]]},"references-count":25,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0273323","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,9]]}}}